Shots:
- Lundbeck has reported P-IIb (PROCEED) trial results evaluating bocunebart (SC/IV; QM for 3mos.) vs PBO in migraine patients with prior failure of 1-4 preventive therapies, with the IV arm randomizing 431 pts across 14 countries
- Trial met its 1EP in the multiple IV dosing arm, showing a statistically significant reduction in monthly migraine days over Wks. 1-12 in pts with prior treatment failures, with further analyses planned to assess dose-response relationships
- Results will be presented at an upcoming conference & submitted for publication, plus Lundbeck is planning to engage regulators to discuss the data & potential P-III design options
Ref: Lundbeck | Image: Lundbeck | Press Release
Related News: Lundbeck Reports the MHLW’s NDA Acceptance of Vyepti (Eptinezumab) for the Preventive Treatment of Migraine
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
